The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
Plant is part of the company's CAD $30 million capital investment in the site
Brings 25 years of global operations and supply chain experience to Piramal
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
The brand has added a range of exciting new products especially formulated for oily skin.
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Subscribe To Our Newsletter & Stay Updated
